BioAmber Inc fka BIOAQ

[GS1]

yes and company didn't do intellectual property or IP auditing so there is no value listed on balance sheet it is bread and butter of any biotech. Biotech patents are hot selling commodity.

As mentioned before they can license technology to company like PTT and collect royalties that is another option may be cheaper but best for shareholders debts will be paid off with upfront amount and collect licensing fees over time. This is best option IMO that way shares continue to trade and appreciate value unless of course buyout happens in large amount will see.

GLTA